Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer

被引：16
|
作者：
Tomasini, Pascale [1 ,2 ]
Greillier, Laurent [1 ,2 ]
Boyer, Arnaud [1 ,2 ]
Jeanson, Arnaud [1 ,2 ]
Barlesi, Fabrice [1 ,2 ]
机构：
[1] Aix Marseille Univ, Multidisciplinary Oncol & Therapeut Innovat Dept, AP HM, Marseille, France
[2] Aix Marseille Univ UM105, Inserm UMR1068, CNRS UMR7258, Predict Oncol Lab,Ctr Rech Cancerol Marseille, Marseille, France
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷
关键词：
TREMELIMUMAB COMBINATION THERAPY; PLATINUM-BASED CHEMOTHERAPY; 1ST-LINE TREATMENT; PLUS TREMELIMUMAB; PATIENTS PTS; MEDI4736; PHASE-3; NSCLC; RADIOTHERAPY; MULTICENTER;
D O I：
10.21037/jtd.2018.04.61
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：S1032 / S1036
页数：5
相关论文
共 50 条
  • [1] Pneumonitis After Chemoradiotherapy and Adjuvant Durvalumab in Stage III Non-Small Cell Lung Cancer
    Edwards, Donna M.
    Sankar, Kamya
    Alseri, Aaren
    Jiang, Ralph
    Schipper, Matthew
    Miller, Sean
    Dess, Kathryn
    Strohbehn, Garth W.
    Moghanaki, Drew
    Ramnath, Nithya
    Green, Michael D.
    Bryant, Alex K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (04): : 963 - 970
  • [2] Durvalumab After Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
    Mooradian, Meghan J.
    Cai, Ling
    Wang, Alice
    Qiao, Yao
    Chander, Pratibha
    Whitaker, Ryan M.
    JAMA NETWORK OPEN, 2024, 7 (04) : e247542
  • [3] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Kim, Young-Hak
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 989 - 990
  • [4] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
    Antonia, S. J.
    Villegas, A.
    Daniel, D.
    Vicente, D.
    Murakami, S.
    Hui, R.
    Yokoi, T.
    Chiappori, A.
    Lee, K. H.
    de Wit, M.
    Cho, B. C.
    Bourhaba, M.
    Quantin, X.
    Tokito, T.
    Mekhail, T.
    Planchard, D.
    Kim, Y. -C.
    Karapetis, C. S.
    Hiret, S.
    Ostoros, G.
    Kubota, K.
    Gray, J. E.
    Paz-Ares, L.
    de Castro Carpeno, J.
    Wadsworth, C.
    Melillo, G.
    Jiang, H.
    Huang, Y.
    Dennis, P. A.
    Ozguroglu, M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20): : 1919 - 1929
  • [5] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer REPLY
    Antonia, Scott J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (10): : 990 - 990
  • [6] Nivolumab Plus Ipilimumab in Relapsed Stage III Non-Small Cell Lung Cancer After Durvalumab Following Chemoradiotherapy
    Tokito, T.
    Mouri, A.
    Watanabe, S.
    Nagai, Y.
    Imai, H.
    Yamaguchi, O.
    Saida, Y.
    Kobayashi, K.
    Kaira, K.
    Kagamu, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S589 - S589
  • [7] Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer
    Huang, Yiqing
    Zhao, Joseph J.
    Soon, Yu Yang
    Wong, Alvin
    Aminkeng, Folefac
    Ang, Yvonne
    Asokumaran, Yugarajah
    Low, Jia Li
    Lee, Matilda
    Choo, Joan R. E.
    Chan, Gloria
    Kee, Adrian
    Tay, Sen Hee
    Goh, Boon Cher
    Soo, Ross A.
    THORACIC CANCER, 2022, 13 (22) : 3152 - 3161
  • [8] Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer
    Chiramel, Jaseela
    Tay, Rebecca
    Califano, Raffaele
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S991 - S994
  • [9] Neoadjuvant Chemoradiotherapy for Stage iii Non-Small Cell Lung Cancer
    Sher, David J.
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [10] Is durvalumab the solution for unresectable stage III non-small cell lung cancer?
    Duma, Narjust
    Mansfield, Aaron S.
    TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S89 - S93
12345